Abstracts tagged "myocardial involvement and systemic lupus erythematosus (SLE)"

Abstract Number: 775 • 2018 ACR/ARHP Annual Meeting
Endomyocardial Biopsies in the Diagnosis of Myocardial Involvement in Systemic Lupus Erythematosus
Laura Geraldino-Pardilla¹, Teja Kapoor², Thania Perez³ and Anca Askanase³, ¹Division of Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ³Columbia University, College of Physicians & Surgeons, New York, NY
Background/Purpose: Myocardial dysfunction is reported in over half of systemic lupus erythematosus (SLE) patients, yet the underlying pathogenesis remains poorly understood. Endomyocardial biopsies (EMBs) are…
Abstract Number: 714 • 2017 ACR/ARHP Annual Meeting
Prolonged Antimalarial Treatment Is Associated with Increased Risk for Elevated Myocardial Biomarkers in Systemic Lupus Erythematosus
Konstantinos Tselios¹, Dafna D Gladman², Paula Harvey³, Shadi Akhtari³, Jiandong Su⁴ and Murray Urowitz², ¹Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Cardiology, Women's College Hospital, University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Antimalarial (AM)-induced cardiomyopathy (AMIC) has been rarely reported in systemic lupus erythematosus (SLE). However, given the large number of patients treated, it seems possible…
Abstract Number: 1782 • 2016 ACR/ARHP Annual Meeting
Subclinical Myocarditis in Systemic Lupus Erythematosus Patients without Cardiovascular Disease
Laura Geraldino-Pardilla¹, Thania Perez², Sabahat Bokhari³, Joan Bathon⁴ and Anca D. Askanase⁵, ¹Division of Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Columbia University College of Physicians & Surgeons, New York, NY, ³Cardiology, Columbia University College of Physicians & Surgeons, NY, NY, ⁴Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ⁵Department of Medicine, Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose : Cardiovascular disease (CVD) remains a leading cause of death in SLE. Lupus patients have a 2-3 fold increased risk to develop heart failure…
Abstract Number: 1819 • 2016 ACR/ARHP Annual Meeting
Myocarditis in Systemic Lupus Erythematosus
Alexandra Perel-Winkler¹, Sabahat Bokhari², Anca D. Askanase³ and Laura Geraldino-Pardilla⁴, ¹Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Cardiology, Columbia University College of Physicians & Surgeons, NY, NY, ³Department of Medicine, Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ⁴Columbia University College of Physicians & Surgeons, new york, NY
Background/Purpose : Cardiovascular disease (CVD) is a leading cause of death in patients with SLE. Lupus patients have a 2-3 fold increased risk of heart…
Abstract Number: 691 • 2014 ACR/ARHP Annual Meeting
Prevalence of Subclinical Echocardiographic Abnormalities in Patients with Systemic Lupus Erythematosus (SLE)
Sergi Heredia¹, Javier Narváez², Andrea Zacarias¹, Eulalia Armengol¹, Gloria Albert¹, Alex Roset³, Patricia Siguenza³, Xavier Juanola⁴, Manel Rubio Rivas³ and Joan Miquel Nolla¹, ¹Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, ³Internal Medicine, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Rheumatology, University Hospital Bellvitge, Barcelona, Spain
Background/Purpose: To determine the prevalence of unsuspected echocardiographic abnormalities (excluding pericardial effusion) and to identify associated clinical and laboratory features in a large SLE cohort.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].